MedTrace Logo

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-05-15

No results posted yet for this study

Summary

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Conditions

Interventions

DRUG

Simbrinza 0.2%-1% Ophthalmic Suspension

brinzolamide and brimonidine tartrate

DRUG

Rocklatan 0.02%-0.005% Ophthalmic Solution

netarsudil and latanoprost

DRUG

Cosopt PF 2%-0.5% Ophthalmic Solution

dorzolamide hydrochloride and timolol maleate

DRUG

Latanoprost 0.005% Ophthalmic Solution

Latanoprost

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Prairie Eye Center

    lead OTHER

Principal Investigators

  • Sandra Yeh, MD · Prairie Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-14
Primary Completion
2026-04-01
Completion
2026-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06883123 on ClinicalTrials.gov